Gene recombination human interferon alpha 2b liposome and injection, suppository, eye drop, sparying preparation and ointment thereof

Abstract

Disclosed is a gene recombinant human interferon alpha 2b liposome comprising the following constituents, bean phospholipin 50-150mg, cholesterin 5-50mg, fatty oil 10-200ug, colloid silicon 10-200ug and interferon. By adding the conventional auxiliary materials into the gene recombinant human interferon alpha 2b liposome, the dosage forms of injection, suppository, eye drops, spray and electuary can be obtained.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations. Specifically, it belongs to the preparation field of gene recombinant human interferon α2b. Background technique [0002] The morbidity and fatality rate of hepatitis B in our country are high, seriously endangering the health and life of patients. Clinical application has confirmed that recombinant human interferon has antiviral, antitumor and immunomodulatory effects, and has been approved in Cuba, the United States and my country for the treatment of hepatitis B, hepatitis C and other viral diseases and tumors. The clinical application results show that the gene recombinant human interferon α is used to treat hepatitis B, but there are disadvantages of low clinical effective rate, large toxic and side effects, and many times of administration. [0003] At present, there are mainly the following problems in interferon therapy: 1) After entering the ...

AI Technical Summary

Problems solved by technology

The results of clinical application show that recombinant human interferon α is used for the treatment of hepatitis B, but it has the disadvantages of low clinical effective rate, large toxic and side effects, and many times of administration

[0003] At present, there are mainly the following problems in the treatment of interferon: 1) After entering the body fluid, it is easily destroyed and inactivated by the enzyme system in the body, and the biological half-life in the body is short

2) Interferon is absorbed and distributed throughout the body, and the amount of interferon reaching the lesion is very limited

Therefore, after intramuscular injection of interferon, the amount of effective drug that reaches the liver and exerts curative effect is very small, which cannot reach the expected curative effect of interferon in the treatment of liver diseases.

3) Long-term application produces antibodies and reduces the curative effect

The existing problems are: the encapsulation efficiency of the existing liposomes still needs to be improved; and the drug has some leakage during the production and storage process, thus losing the inherent protection drug of the liposome and improving the stability; ultimately lead to a decrease in the efficacy of the drug

The disadvantage is that the stability is still poor, which is not conducive to the storage of finished products such as injections, suppositories, eye drops, sprays, ointments, etc.